A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending oral dose studies with or without ritonavir in healthy adult volunteers.
GLS4 is a novel inhibitor of the hepatitis B virus (HBV) capsid assembly with inhibitory activities against nucleot(s)ide-resistant HBV strains. This study investigated the pharmacokinetics, safety, and tolerability of GLS4 and the effects of food and ritonavir in healthy adults. GLS4 was administered in a single-ascending-dose study over 1-240 mg and multiple-ascending-dose study that ranged from 30 mg once daily to 180 mg thrice daily. The drug interaction study included sequential-design (day 1 for 120 mg GLS4 alone, day 5 for 100 mg ritonavir alone followed by 9 days of both drugs) and a placebo-control (9 days of both 240 mg GLS4 and 100 mg ritonavir). The results showed that the steady-state trough concentration of multiple dosing of GLS4 alone was significantly lower than the 90% effective concentration (EC90) of 55.7 ng/ml, even with increasing dosing frequency and dosage. An initial dose of 100 mg ritonavir significantly boosted plasma concentration at 24 h of 120 mg GLS4 from 2.40 ng/ml to 49.8 ng/ml (geometric mean ratio of 20.7, 90% confidence interval 17.0-25.3), while a milder effect was observed on the area under the curve (AUC)0-24h with a 7.42-fold increase and on Cmax, with a 4.82-fold increase. The pharmacokinetics change in GLS4 persisted after 9 days of chronic dosing, with a trough concentration of 182 ng/ml. Both single and multiple doses of GLS4 up to 240 mg with or without ritonavir were well tolerated. These results support the investigation of a novel HBV treatment regimen containing GLS4 with 100 mg ritonavir added solely to enhance GLS4 concentrations in plasma.